- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05251909
Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) (HUDSON GI)
February 19, 2024 updated by: AstraZeneca
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to Demonstrate the Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)
This is a 3-part study.
Part A is randomized, double-blinded, placebo-controlled and includes patients with eosinophilic gastritis and/or duodenal-only disease.
After completing Part A, participants can continue to Part C - open-label benralizumab treatment period.
Following the decision to close enrollment, patients in both Part A and Part C will be given the option to proceed to 6-months of open-label benralizumab treatment in Part D.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The aim of this Phase 3 study is to investigate the use of benralizumab as a treatment for patients with Eosinophilic Gastritis and/or Gastroenteritis.
The effect of doses of benralizumab on EG/EGE histologic signs and symptoms will be assessed in a 24-week double-blind placebo-controlled treatment period followed by assessments during an open-label benralizumab treatment period.
It is proposed that benralizumab will deplete eosinophilis, improve the symptoms in patients with eosinophilic gastritis and/or gastroenteritis, and improve histologic scores as well as other markers of disease activity.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Sao Paulo, Brazil, 01327-001
- Research Site
-
-
-
-
-
Milano, Italy, 20122
- Research Site
-
Padova, Italy, 35128
- Research Site
-
Pisa, Italy, 56124
- Research Site
-
-
-
-
-
Bunkyo-ku, Japan, 113-8603
- Research Site
-
Maebashi-shi, Japan, 371-8511
- Research Site
-
Ogaki-shi, Japan, 503-8502
- Research Site
-
Shinjuku-ku, Japan, 162-8655
- Research Site
-
-
-
-
-
Amsterdam, Netherlands, 1105 AZ
- Research Site
-
-
-
-
-
Staszów, Poland, 28-200
- Research Site
-
-
-
-
-
Sevilla, Spain, 41009
- Research Site
-
-
-
-
-
Kyiv, Ukraine, 04050
- Research Site
-
-
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Research Site
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Research Site
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- Research Site
-
Salt Lake City, Utah, United States, 84107
- Research Site
-
-
-
-
-
Hanoi, Vietnam, 100000
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 130 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion criteria:
- Aged >= 12 years of age at the time of signing the ICF or informed consent or assent form.
- Confirmed diagnosis of EG/EGE for at least 3 months prior to screening.
- Baseline Eosinophilic gastritis, with or without duodenitis, or eosinophilic duodenitis alone confirmed by biopsy with a gastric count of ≥30 eosinophils/hpf in at least 5 hpfs and/or duodenal eosinophil count ≥30 eosinophils/hpf in at least 3 hpfs without any other cause for the gastrointestinal eosinophilia.
- Symptoms including at least moderate abdominal pain, nausea, bloating, early satiety, and/or loss of appetite
- Must be adherent to daily PRO assessments including at least 8 of 14 symptom assessments in the 14 days prior to randomization
- If on background medications for EG/EGE, the medications should be stable at least 4 weeks prior to the run-in period.
- Willing and able to comply with all study procedures and visit schedule including follow-up visits
- Women of childbearing potential must agree to use a highly effective form of birth control (confirmed by the Investigator) from randomization throughout the study duration and within 12 weeks after last dose if IP.
Exclusion criteria:
- Other gastrointestinal disorders such as active Helicobacter pylori infection, history of achalasia, esophageal varices, Crohn's disease, ulcerative colitis, inflammatory bowel disease, or celiac disease.
- Hypereosinophilic syndrome or eosinophilic granulomatosis with polyangiitis.
- Current malignancy, or history of malignancy, except for patients who have had basal cell, localized squamous cell carcinoma of the skin, or in situ carcinoma of the cervix are eligible provided that the patient is in remission and curative therapy was completed at least 12 months prior to the date of informed consent.
- History of anaphylaxis to any biologic therapy or vaccine.
- Current active liver disease.
- Helminth parasitic infection diagnosed within 24 weeks prior to the date informed that has not been treated with or has failed to respond to standard of care therapy.
- Known immunodeficiency disorder including testing positive for HIV.
- Concomitant use of immunosuppressive medication.
- Receipt of live attenuated vaccines 30 days prior to date of informed consent or assent.
- Receipt of inactive vaccines within 7 days of informed consent or assent.
- Initiation or change of a food-elimination diet regimen or re-introduction of a previously eliminated food group from 6 weeks prior to start of the run-in period and unable or unwilling to remain on a stable diet until the completion of Part A and C.
- Currently pregnant or breast-feeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Benralizumab
This arm is a subcutaneous dose of Benralizumab
|
Benralizumab is a humanized, afucosylated, monoclonal antibody that binds specifically to the IL-5Rα on the target cell and thus directly depletes eosinophils through antibody-dependent cell-mediated cytotoxicity.
Benralizumab has been widely approved for treatment of asthma.
Other Names:
|
Placebo Comparator: Placebo
This arm is a subcutaneous dose of Placebo
|
Placebo will be injected as a comparator to injection with Benralizumab to examine effect on both the signs and symptoms of EG/EGE and the underlying eosinophilic inflammation, with dual primary outcome variables
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients achieving a histological response in the stomach and/or in the duodenum
Time Frame: Week 24
|
Given the decision to stop recruitment to the study, it will not be possible to assess objectives with the data collected during Part A.
|
Week 24
|
Absolute change from baseline in SAGED (Symptom Assessment for Gastrointestinal Eosinophilic Diseases) Score (range: 0-50). SAGED score measures gastrointestinal symptoms with higher scores meaning worse outcome
Time Frame: Week 24
|
Given the decision to stop recruitment to the study, it will not be possible to assess objectives with the data collected during Part A.
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent change in tissue eosinophils
Time Frame: Week 24
|
Given the decision to stop recruitment to the study, it will not be possible to assess objectives with the data collected during Part A.
|
Week 24
|
Proportion achieving treatment response
Time Frame: Week 24
|
Given the decision to stop recruitment to the study, it will not be possible to assess objectives with the data collected during Part A.
|
Week 24
|
Diarrhea-free days
Time Frame: Week 24
|
Given the decision to stop recruitment to the study, it will not be possible to assess objectives with the data collected during Part A.
|
Week 24
|
Frequency of diarrhea episodes
Time Frame: Week 24
|
Given the decision to stop recruitment to the study, it will not be possible to assess objectives with the data collected during Part A.
|
Week 24
|
Vomiting-free days
Time Frame: Week 24
|
Given the decision to stop recruitment to the study, it will not be possible to assess objectives with the data collected during Part A.
|
Week 24
|
Frequency of vomiting episodes
Time Frame: Week 24
|
Given the decision to stop recruitment to the study, it will not be possible to assess objectives with the data collected during Part A.
|
Week 24
|
Proportion of patients with no rescue corticosteroid use
Time Frame: Week 24
|
Given the decision to stop recruitment to the study, it will not be possible to assess objectives with the data collected during Part A.
|
Week 24
|
Health-related quality of life measured as change from baseline in SF-36v2 (the Short Form 36-item Health Survey, Version 2) which has two components: Physical Component Summary (PCS) and Mental Component Summary (MCS).
Time Frame: Week 24
|
The score range for PCS and MCS is 0-100; higher scores indicate better health state. Given the decision to stop recruitment to the study, it will not be possible to assess objectives with the data collected during Part A. |
Week 24
|
Diarrhea and constipation free days
Time Frame: Week 24
|
Given the decision to stop recruitment to the study, it will not be possible to assess objectives with the data collected during Part A.
|
Week 24
|
Clinically meaningful symptom change. Time to clinically meaningful change in SAGED score (range: 0-50) measures gastrointestinal symptoms with higher scores meaning worse outcome.
Time Frame: Week 24
|
Given the decision to stop recruitment to the study, it will not be possible to assess objectives with the data collected during Part A.
|
Week 24
|
PROMIS Fatigue 7a score
Time Frame: Week 24
|
Given the decision to stop recruitment to the study, it will not be possible to assess objectives with the data collected during Part A.
|
Week 24
|
PAGI-QoL score
Time Frame: Week 24
|
Given the decision to stop recruitment to the study, it will not be possible to assess objectives with the data collected during Part A.
|
Week 24
|
PAGI-SYM score
Time Frame: Week 24
|
Given the decision to stop recruitment to the study, it will not be possible to assess objectives with the data collected during Part A.
|
Week 24
|
Pharmacokinetics of benralizumab in patients (with EG/EGE)
Time Frame: Minimum 24 weeks
|
Given the decision to stop recruitment to the study, it will not be possible to assess objectives with the data collected during Part A.
|
Minimum 24 weeks
|
Immunogenicity of benralizumab in patients (with EG/EGE)
Time Frame: Minimum 24 weeks
|
Given the decision to stop recruitment to the study, it will not be possible to assess objectives with the data collected during Part A.
|
Minimum 24 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability - Incidence of Treatment-Emerged AEs and SAEs
Time Frame: Week 52
|
Adverse Events (AEs) and Serious Adverse Events (SAEs)
|
Week 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Marc E. Rothenberg, MD, PhD, Cincinnati Children's Hospital Medical Center 3333 Burnet Ave, Cincinnati Ohio 45229, United States
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 18, 2022
Primary Completion (Actual)
February 13, 2024
Study Completion (Actual)
February 13, 2024
Study Registration Dates
First Submitted
August 6, 2021
First Submitted That Met QC Criteria
February 15, 2022
First Posted (Actual)
February 23, 2022
Study Record Updates
Last Update Posted (Actual)
February 20, 2024
Last Update Submitted That Met QC Criteria
February 19, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Hematologic Diseases
- Gastrointestinal Diseases
- Stomach Diseases
- Intestinal Diseases
- Hypersensitivity
- Esophageal Diseases
- Esophagitis
- Leukocyte Disorders
- Gastritis
- Gastroenteritis
- Eosinophilic Esophagitis
- Enteritis
- Eosinophilia
- Anti-Asthmatic Agents
- Respiratory System Agents
- Benralizumab
Other Study ID Numbers
- D3258C00001
- 2021-000085-14 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers can request access to anonymised individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the de- identified individual patient-level data in an approved sponsor tool.
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.
For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eosinophilic Gastritis
-
Children's Hospital Medical Center, CincinnatiAstraZenecaCompletedEosinophilic Gastritis or GastroenteritisUnited States
-
Allakos Inc.CompletedEosinophilic Gastritis | Eosinophilic DuodenitisUnited States
-
Children's Hospital Medical Center, CincinnatiNational Institute of Allergy and Infectious Diseases (NIAID); National Institute... and other collaboratorsCompletedEosinophilic Gastritis | Eosinophilic Gastroenteritis | Eosinophilic Esophagitis | Eosinophilic ColitisUnited States
-
Arkansas Children's Hospital Research InstituteWithdrawnEosinophilic Gastritis | Eosinophilic Esophagitis | Eosinophilic Colitis | Eosinophilic EnteritisUnited States
-
Allakos Inc.CompletedEosinophilic Gastritis | Eosinophilic Gastroenteritis | Eosinophilic DuodenitisUnited States
-
Children's Hospital Medical Center, CincinnatiNational Institute of Allergy and Infectious Diseases (NIAID); National Institute... and other collaboratorsRecruitingEosinophilic Gastritis | Eosinophilic Gastroenteritis | Eosinophilic Esophagitis | Eosinophilic Colitis | Eosinophilic Gastrointestinal Disorders (EGIDs)United States
-
IRCCS Policlinico S. MatteoItalian Society of Pediatric Allergy & Immunology - Pediatric CentersRecruitingEosinophilic Esophagitis | Eosinophilic Colitis | Eosinophilic Gastritis or Gastroenteritis | Eosinophilic Gastrointestinal DisordersItaly
-
Allakos Inc.CompletedEosinophilic Gastritis | Eosinophilic GastroenteritisUnited States
-
Children's Hospital Medical Center, CincinnatiNational Institutes of Health (NIH); Regeneron PharmaceuticalsActive, not recruitingEosinophilic Gastritis | Eosinophilic GastroenteritisUnited States
-
Regeneron PharmaceuticalsSanofiRecruitingEosinophilic Gastritis | Eosinophilic Duodenitis | Eosinophilic Gastrointestinal DiseaseUnited States, Poland, Italy, Japan, Australia
Clinical Trials on Benralizumab
-
AstraZenecaMedImmune LLCCompletedModerate to Very Severe Chronic Obstructive Pulmonary DiseaseUnited States, Denmark, France, Sweden, Thailand, Vietnam, Belgium, Brazil, Peru, Philippines, Turkey, Taiwan, Argentina, Australia, Israel, Poland, Ukraine, Slovenia, Serbia, Mexico, Bulgaria, Colombia, New Zealand, Chile, Norway, Croatia
-
AstraZenecaIqvia Pty LtdTerminatedChronic Spontaneous UrticariaUnited States, Germany, Korea, Republic of, Spain, Bulgaria, Poland, Japan
-
MedImmune LLCCompleted
-
AstraZenecaIqvia Pty LtdTerminatedAtopic DermatitisUnited States, France, Korea, Republic of, Spain, Czechia, Bulgaria, Australia, Poland
-
AstraZenecaMedImmune LLCCompletedModerate to Very Severe Chronic Obstructive Pulmonary DiseaseUnited States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland
-
MedImmune LLCMedImmune LtdCompletedAsthmaUnited States, Brazil, Bulgaria, Mexico, Peru, Poland, Russian Federation, Argentina, Canada, Colombia
-
Instituto de Investigación Sanitaria de la Fundación...CompletedAsthma; EosinophilicSpain
-
AstraZenecaCompletedNasal Polyps | Severe Eosinophilic AsthmaUnited States, France, Italy, Spain, Germany, Japan
-
Jonathan A. Bernstein, MDCompletedChronic Idiopathic UrticariaUnited States
-
AstraZenecaCompletedAsthmaUnited States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom